ABD778 augmented the anti-leukemia activity of the pan-PI3 kinase inhibitor pictilisib<sup>9</sup>, the K/N-Ras<sup>G12C</sup> inhibitor sotorasib<sup>10</sup>, and the FLT3 inhibitor gilteritinib<sup>11</sup>. This evidence concerns the gene NRAS and leukemia.